Insmed, Inc. $INSM Shares Sold by Holocene Advisors LP

Holocene Advisors LP decreased its holdings in Insmed, Inc. (NASDAQ:INSM) by 46.3% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 1,083,681 shares of the biopharmaceutical company’s stock after selling 933,125 shares during the period. Holocene Advisors LP’s holdings in Insmed were worth $156,061,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. EULAV Asset Management acquired a new stake in shares of Insmed in the third quarter worth $12,961,000. Resolute Capital Asset Partners LLC acquired a new position in shares of Insmed during the 2nd quarter valued at $2,748,000. Nisa Investment Advisors LLC boosted its position in Insmed by 374.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company’s stock worth $1,507,000 after purchasing an additional 8,261 shares during the period. Atika Capital Management LLC purchased a new stake in Insmed during the 3rd quarter worth $13,681,000. Finally, Keybank National Association OH increased its holdings in Insmed by 76.7% in the 3rd quarter. Keybank National Association OH now owns 16,716 shares of the biopharmaceutical company’s stock valued at $2,407,000 after purchasing an additional 7,257 shares in the last quarter.

Insiders Place Their Bets

In other Insmed news, COO Roger Adsett sold 791 shares of Insmed stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $156.17, for a total transaction of $123,530.47. Following the sale, the chief operating officer directly owned 106,810 shares in the company, valued at $16,680,517.70. The trade was a 0.74% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $146.03, for a total value of $1,562,374.97. Following the completion of the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at approximately $43,982,045.55. The trade was a 3.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 189,651 shares of company stock valued at $31,784,545 over the last 90 days. 3.00% of the stock is owned by company insiders.

Insmed Stock Performance

NASDAQ:INSM opened at $139.50 on Monday. The firm has a 50-day moving average of $155.18 and a two-hundred day moving average of $166.16. The company has a debt-to-equity ratio of 0.76, a current ratio of 3.83 and a quick ratio of 3.54. The stock has a market cap of $30.07 billion, a P/E ratio of -21.76 and a beta of 1.13. Insmed, Inc. has a 1-year low of $60.40 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last announced its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The business had revenue of $263.84 million for the quarter, compared to analysts’ expectations of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The firm’s revenue was up 152.6% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.32) earnings per share. On average, research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on INSM shares. Citigroup restated an “outperform” rating on shares of Insmed in a research note on Thursday, December 18th. HC Wainwright reiterated a “buy” rating and set a $230.00 target price on shares of Insmed in a report on Monday, February 23rd. Cantor Fitzgerald boosted their price target on Insmed from $216.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Morgan Stanley set a $166.00 price target on Insmed in a report on Friday, February 20th. Finally, Jefferies Financial Group set a $269.00 price objective on shares of Insmed in a research report on Wednesday, December 10th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Insmed currently has an average rating of “Buy” and an average target price of $207.52.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.